Actually, the pharmacological therapy for DMD includes nitric oxide (NO) administration, insulin-like growth factor 1 (IGF-1) stimulation, and myostatin inhibition in way to increase skeletal muscle mass; otherwise, therapies leading the inhibition of the transforming growth factor-beta (TGFβ) pathway, modulation of nuclear factor-κB (NF-κB), and tumor necrosis factor-α (TNF-α) signalling are used to reduce fibrosis and inflammation in muscle [15]. Here, TNF is linked to Duchenne muscular dystrophy.